-
BODIPY 581/591 C11 for Ferroptosis Assays
2026-09-17
BODIPY 581/591 C11 converts membrane lipid oxidation into a ratiometric red-to-green signal, enabling more reliable lipid peroxidation detection than single-channel intensity assays. This workflow shows how to apply it to endothelial ferroptosis, antioxidant capacity evaluation, live-cell imaging, and high-content oxidative stress measurement.
-
Phosphatase Inhibitor Cocktail 2 Workflow Guide
2026-09-16
Build reliable phosphoprotein workflows with broad-spectrum protection from lysis through Western blotting, co-immunoprecipitation, imaging, and kinase assays. Phosphatase Inhibitor Cocktail 2 combines operational simplicity with practical safeguards for studying signaling and metabolic regulation in complex tissue extracts.
-
Fingolimod (FTY720) Research Workflows
2026-09-15
Fingolimod (FTY720) supports controlled studies of S1P signaling, lymphocyte trafficking, cancer-cell viability, and CNS-associated BDNF responses. This practical guide separates receptor-level immunomodulation from the magnetic CAR-T-mimicking platform described in the reference study, helping researchers choose cleaner controls and troubleshoot assays.
-
Disodium Bicinchoninate: Translational Assay Strategy
2026-09-15
A thought-leadership guide to using Disodium bicinchoninate as an aqueous assay-design variable in endothelial dysfunction research, with mechanistic context from H2O2, inflammation, autophagy, and EZH2 biology.
-
Direct Mouse Genotyping Kit Plus: PCR Workflow
2026-09-14
The Direct Mouse Genotyping Kit Plus combines rapid mouse tissue lysis with direct PCR and a PCR master mix with dye reagents. The workflow reduces purification steps while preserving the need for validated primers, controls, and phenotype-specific assays.
-
MLN2238: From Target Engagement to Stress Biology
2026-09-14
MLN2238 is a reversible proteasome β5 subunit inhibitor that connects catalytic target engagement with ROS–JNK–CREB stress signaling. This guide presents a mechanistic assay framework for oncology, proteostasis, multiple myeloma research, and lymphoma research without confusing proteasome inhibition with downstream toxicity.
-
Pepstatin A: A Protease-Aware Assay Strategy
2026-09-13
Pepstatin A is an aspartic protease inhibitor that can clarify enzyme-dependent phenotypes in viral, lysosomal, and bone biology studies. This article combines product performance with a GABA receptor trafficking study to show how inhibitor experiments can distinguish proteolysis from broader protein-processing defects.
-
PPARα Activation and Pyroptosis in Liver Injury
2026-09-12
A 2026 Liver Research study identifies two pyroptotic pathways through which PPARα activation protects mice from lithocholic acid-induced cholestatic liver injury. Its combination of morphology, serum biochemistry, gene and protein analyses, and co-immunoprecipitation provides a mechanistic framework for studying PPARα beyond lipid metabolism regulation.
-
Rotigotine Analytical Methods: Purity, Stability, Impurities
2026-09-12
This review consolidates chromatographic and related analytical methods for Rotigotine raw material, transdermal patches, enantiomeric purity, and degradation products. Its main practical contribution is to connect pharmacopoeial procedures with impurity and stability considerations, while identifying gaps in the toxicological and pharmacokinetic characterization of Rotigotine-related substances.
-
N-MYC–eIF4G1 Axis in inv(16) AML
2026-09-11
This Science Advances study identifies an oncogenic N-MYC/eIF4G1 survival axis in inv(16) acute myeloid leukemia and defines a previously unrecognized MYCN enhancer that supports leukemic maintenance. Its integrated use of transcriptomic reanalysis, regulatory-element analysis, human leukemia models, and patient-derived xenografts provides a framework for connecting leukemia-specific transcriptional control to therapeutic vulnerability.
-
ARL4C Drives RA Fibroblast and Macrophage Dynamics
2026-09-11
The reference study integrates single-cell and bulk transcriptomics with ARL4C perturbation, FLS–macrophage co-culture, and collagen-induced arthritis experiments. Its findings position ARL4C as a regulator of aggressive fibroblast-like synoviocytes, macrophage polarization, PI3K/AKT and MAPK signaling, and joint damage, while identifying testable opportunities for orthogonal cell-cycle validation.
-
Pepstatin A for Aspartic Protease Workflows
2026-09-10
Pepstatin A enables selective interrogation of aspartic proteases across biochemical, viral protein processing, and osteoclast models. This practical guide connects inhibitor handling with assay design, controls, and the macrophage ACE2 findings of a recent SARS-CoV-2 study.
-
Ensemble-Based uPAR–uPA Inhibition and Cell Invasion
2026-09-10
The reference study introduced an ensemble-based virtual screening strategy to identify small-molecule inhibitors of the difficult uPAR·uPA protein–protein interaction. IPR-456 and related compounds demonstrated direct target engagement and reduced uPA binding and invasion in breast cancer cells, while the separation of invasion from migration and adhesion clarified the pathway’s biological specificity.
-
Sulforaphane Workflows for Redox and Inflammation
2026-09-09
Build reproducible Sulforaphane workflows that connect Keap1–Nrf2 signaling, cancer chemoprevention assays, and NLRP3-focused inflammation models. This guide translates mouse colitis findings into practical cell-culture, animal-study, assay-selection, and troubleshooting decisions.
-
Amorolfine Hydrochloride: Mapping Membrane Limits
2026-09-09
A translational perspective on using Amorolfine Hydrochloride to connect fungal membrane-synthesis perturbation with ploidy, cell-surface stress, and antifungal resistance studies. The article integrates budding-yeast evidence with practical assay design while distinguishing established findings from research hypotheses.